TMO Thermo Fisher Scientific Inc.
USHealthcareAs of 2026-08-24
Why TMO matters now
Thermo Fisher Scientific Inc. (TMO) is a US stock in Healthcare. The latest InvestLog snapshot shows $628.87 with -0.06% on the session and $233.70B in market capitalization; recent performance reads 1-month +3.75% and YTD -19.82%.
The latest financial table shown here is Q1 2026, with revenue of $11.01B, net income of $1.65B, and EPS of $4.43. Investors can compare that operating picture with valuation signals such as P/E 27.08 and FCF yield 3.9%.
InvestLog's latest related AI research is a Insider Sale note titled "Casper Marc N sells $12.8M of TMO". The latest indexable market news headline is "Is TMO Overvalued? DCF Says Worth $491" from GuruFocus.
Additional event context on this page matters because analyst consensus is Buy with a median target of $617.50; recent insider activity includes Chai Nelson filing A-Award; recent congressional disclosure data includes Dwight Evans Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
27.08
PEG
4.53
P/B
3.33
P/S
3.82
EV/EBITDA
19.05
DCF Value
$549.27
FCF Yield
3.9%
Div Yield
0.4%
Margins & Returns
Gross Margin
39.4%
Operating Margin
17.8%
Net Margin
15.2%
ROE
13.3%
ROA
6.1%
ROIC
7.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $11.01B | $1.65B | $4.43 |
| Q4 2025 | $12.21B | $1.98B | $5.21 |
| FY 2025 | $44.56B | $6.74B | $17.74 |
| Q3 2025 | $11.12B | $1.62B | $4.27 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$599.70
Target (Median)
$617.50
Target Range
$490.00 - $683.00
Trading Activity
Insider Trades
Congress Trades
Related AI Research
Casper Marc N sells $12.8M of TMOCasper Marc N 内部减持 赛默飞 (TMO) $12.8M
On August 21, 2026, Casper Marc N, Chairman & CEO, Director, and Officer of Thermo Fisher Scientific (Ticker: TMO), sold 20,321 common shares on the open market at $628.11 per share, for a total.2026年8月21日,赛默飞世尔科技(股票代码:TMO)董事长兼首席执行官、董事兼高管CASPER MARC N以每股628.11美元的公开市场价格出售20,321股普通股,交易总价值12,763,764.31美元,相关Form 4内幕交易申报文件于2026年8月24日提交至美国SEC。该笔交易占TMO当前2337亿美元总市值的0.005%,属于小额持仓调整。
Thermo Fisher Scientific Inc. (TMO) 2026 Q2 period ended 2026-06-27 financial resultsThermo Fisher Scientific Inc. (TMO) 2026 Q2 period ended 2026-06-27 财报发布
Thermo Fisher Scientific Inc. reported revenue $12.0B, operating profit $2.1B, net income $1.7B, operating margin 17.4%.Thermo Fisher Scientific Inc. 公布2026 Q2 period ended 2026-06-27财报:营收 $12.0B,营业利润 $2.1B,净利润 $1.7B,营业利润率 17.4%。
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
0.87
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.